Regarding “Early rupture and degeneration of cryopreserved arterial allografts”  by unknown
LETTERS TO THE EDITORS
Regarding "Early rupture and degeneration of
cryopreserved arterial allografts"
To the Editors:
Lehalle and associates report early postoperative rupture
and major dilatation ofcryopreserved arterial allografts used
to treat vascular infection (J Vase Surg 1997;25:751-2).
They assume that current cryopreservation techniques are
responsible for making allografts more brittle. They argue
with an experimental study demonstrating intimomedial fis-
sures and modulation of the elastic property of cattle vessels
after cryopreservation1 and conclude that implanting cry-
opreserved arterial grafts carries a risk of secondary rupture.
Since 1988 we have used cryopreserved heart valve and
arterial homografts to treat major cardiovascular infections.
The use of cryopreserved arterial homografts2,3 was stimu-
lated by our experience5 with heart valve homografts for the
treatment of infectious endocarditis, as the root replace-
ment technique always implied the implantation of a large-
caliber cryopreserved artery-the proximal two thirds ofthe
ascending aorta-in an infected field. During a mean fol-
low-up of 5 years, we never observed early or late postoper-
ative problems concerning the cryopreserved aorta.
In situ repair with cryopreserved arterial homografts
was performed in 35 patients who had mycotic aneurysms
or prosthetic graft infection of the thoracic and abdominal
aorta, pelvic and groin vessels. The overall 30-day mortality
rate was 5.7%, whereas the infection-related mortality rate
was 2.8%. Two patients (6%) died oflate acute hemorrhag-
ic shock, caused by an aortoenteric fistula originating from
the stump of the inferior mesenteric artery of the homo-
graft. Early disruption or aneurysm formation of cryopre-
served homografts as described by Lehalle was not
observed.
In our opinion, the use of cryopreserved homografts to
treat major cardiovascular infection is safe and cost-effective,
and reduces the operative mortality rate and the incidence
of reoperation.
In addition, explanted cryopreserved heart valve and
arterial homografts were compared using microscopy and
immunohistochemical examinations: CD45RO, CD3, and
CD43 to detect T-celllymphoeytes, CD20 for B-cell lym-
phocytes, CD68 for macrophages, and protein S100 for
Langerhans cells. All homografts were fibrotic, acellular,
nonvital, and without endothelial cells. Ground substance
and collagen skeleton were intact and elastic fibers partly
preserved. Heart valve homografts showed B-cell lympho-
cyte; arterial homografts showed B-cell and limited T-cell
infiltration.
We think that cryopreserved arterial homografts under-
go a limited cellular and humoral rejection. Nevertheless,
their glucoseamino-glycane matrix and collagen skeleton
seem to be preserved. This is in contrast to the breakdown
of freshly implanted homografts, in which the immunolog-
ically mediated rejection results in progressive degeneration
of the elastic fibers and collagen connective tissue.
Moreover, the infiltration of macrophages and Langerhans
cells causes rarification of the tissue and necrosis.6 This leads
to a loss of the mechanical strength, aneurysm formation,
and rupture, a sequence that was never observed in our cry-
opreserved arterial homografts.
Therefore, we wonder whether the cryopreservation
protocol used by Lehalle and associates is the reason for
their findings. Although they describe morphologic changes
in cryopreserved cattle vessels, l we would be interested in
the detailed pathologic changes of their arterial homografts
that showed early rupture and degeneration. The cryop-
reservation protocol used by the European Homograft
Bank6 provides durable homografts. As long as 7 years after
implantation, neither anastomotic aneurysm, thrombosis,
or spontaneous rupture as described for fresWy implanted
homografts7 have been found in our cryopreserved arterial
homografts.
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